To download click here

To view the presentation click here

If you wish to see the full unedited version of this presentation please click here

Dutch group ISA Pharmaceutical will incorporate its Amplivant technology into Modi-1, the first cancer treatment candidate being developed on the platform

[View article]

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), spoke to Proactive soon after taking over as CEO at the immuno-oncology company.

Holloway says generating clinical data's a big focus for them in the near-term.

''Over the next two years we expect to see clinical readouts from two of our programmes - SCIB1 and Modi-1''.

''We'll be extending our pipeline particularly around Moditope with the Modi-3 programme, if we're successful with the grand challenge''.

''Then it's around looking at technical partnerships that will allow us to de-risk our developments''.

[View interview]

To download click here

Immuno-therapy SCIB1, which is expected to progress into Phase II clinical trials in the second-half of the year, was the focus of a peer-reviewed paper in OncoImmunology

[View article]

To download click here

To download click here

Once formally granted, the patent will provide protection for Scancell’s pipeline of Moditope vaccines

[View article]

The Cancer Research UK Grand Challenge is a prestigious award that brings with it significant funding

[View article]